2023

Permanent URI for this collection

Now showing 1 - 1 of 1

Identification of HUB genes from microarray and RNAseq datasets of localized prostate cancer and their interaction with FDA approved drugs.
(UMT Lahore, 2023-08-11) AMAN NIHAL; AKIF BURHAN; AFEERA FAROOQ
Prostate cancer is a cancer that occurs in the prostate gland. It is one of the common types of cancer in males as it affects one in seven men. In our study we aimed to identify hub genes that have a role to play in the occurrence of cancer and to analyze their interaction levels with FDA approved drugs. To those means we used microarray datasets GSE46602 (36 PCa patients and 14 controls), GSE69223 (15 PCa patients and 15 controls), GSE30994 (3 PCa patients and 3 controls) and a RNA seq dataset GSE104131 (16 PCa patients and 16 controls). By taking a bioinformatics approach we were able to identify ten hub genes (CAV1, GSTM3, GSTM4, CYP3A5, PRKCA. GJA1, PGR, S100A6, ACSS3 and AOX1). We took forward the top 3 of these genes and docked them with the FDA approved drugs we selected after screening them. We achieved docking results with Bicalutamide, Estramustine, Enzalutamide, Rucaparib, Olaparib, Apalutamide and Darolutamide. We were able to conclude that the identified hub genes all have potential to act as biomarkers for localized prostate cancer, and that GSTM4 can be considered as a useful element in the prognosis of prostate cancer based on its significant interaction with the FDA approved drugs.